CFTX-1554 is under clinical development by Confo Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CFTX-1554’s likelihood of approval (LoA) and phase transition for Fibrosis took place on 15 Mar 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 15 Mar 2022 decreased CFTX-1554’s LoA and PTSR for Neuropathic Pain (Neuralgia).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CFTX-1554 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CFTX-1554 overview

CFTX-1554 is under development for the treatment of neuropathic pain and fibrosis. The drug candidate acts by targeting angiotensin II type 2 receptor (AGTR2). The drug candidate is based on CONFO technology.

Confo Therapeutics overview

Confo Therapeutics operates as a drug discovery company that conducts research and development of g protein coupled receptors targeted therapeutics. The company offers CONFO body technology. Its technology uses confobody stabilized functional conformations of g protein coupled receptors. Confo Therapeutics stabilizes the druggable signaling conformation of g protein coupled receptors targeting to enable screening for pathway selective agonists, enable structure-based drug design and develop a pipeline of agonist drugs against selected high value g protein coupled receptors. The company’s CONFO body technology recognizes discontinuous amino acid segments on native proteins. It operates offices in Ghent and Brussels, Belgium. Confo Therapeutics is headquartered in Brussels, Belgium.

Quick View CFTX-1554 LOA Data

Report Segments
  • Innovator
Drug Name
  • CFTX-1554
Administration Pathway
Therapeutic Areas
  • Central Nervous System
  • Musculoskeletal Disorders
Key Developers
  • Sponsor Company: Confo Therapeutics
  • Originator: Stanford University, University of Michigan and Vrije University Brussel
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.